Polycystic ovary syndrome (PCOS) is the most common endocrine disorder seen in the clinic, with a prevalence depending on the diagnostic criteria utilized. 1 PCOS affects approximately 10% of women according to the currently-recommended Rotterdam diagnostic criteria, which include evidence of at least two of the following: clinical and/or biochemical hyperandrogenism, chronic oligo-or anovulation, and polycystic ovarian morphology. [1][2][3] The prevalence of PCOS is approximately 6% according to the classic National Institutes of Health (NIH) definition of PCOS, which mandates both hyperandrogenism and ovulatory dysfunction. 1,4 Finally, PCOS affects approximately 10% of women according to the Androgen Excess and PCOS Society criteria: hyperandrogenism plus either ovulatory dysfunction or polycystic ovarian morphology. 1,5 PCOS has also been associated with several comorbidities, including obesity, insulin resistance and type 2 diabetes, depression and anxiety, obstructive sleep apnea, and endometrial cancer. [6][7][8][9][10][11][12] Although the characteristics that define PCOS (i.e., androgen excess, oligo-/anovulation and polycystic ovarian morphology) are most directly related to ovarian function, the central reproductive neuroendocrine system, particularly the gonadotropin-releasing